Clinical Trials
4 trialsNCT02487979 2022-01-18
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02363283 2020-08-21
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01997333 2019-03-08
METRIC
Celldex Therapeutics
Phase 2 Completed
NCT01156753 2017-07-02
EMERGE
Celldex Therapeutics
Phase 2 Completed